TCT 2020 | The Myth of Biodegradable Polymers Seems to Have Come to an End

This is the largest and newest study to compare drug eluting stents with durable polymers vs. biodegradable or bioresorbable polymers. As is usually the case, the theory clashes with reality. 

The study has shown that the polymer does not seem to play an important role in the performance of drug eluting stents, or at least this is what happens in the acute coronary syndrome population. 

The durable polymer not only resulted non-inferior to the biodegradable polymer, but it also showed some technical advantages. 

Many doctors and companies believed in the theory behind biodegradable polymers, but this theoretical benefit was never confirmed by clinical studies.

For the new DES generations, strut thickness and design play a far more important role than the drug or the polymer. 


Read also: TCT 2020 | New Information about Pre and Post PCI FFR Value.


The study included 3400 patients undergoing acute coronary syndrome. This population was chosen especially, since they are known for being at higher risk of thrombosis and healing slower. This is where biodegradable polymer DES should have proven more beneficial.  

1730 patients received durable polymer DES (Promus, Resolute Onyx and Xience) and 1700 received biodegradable polymer DES (Ultimaster, Orsiro and Biomatrix Flex).

The combined end point of death, MI, stent thrombosis and revascularization at one year resulted similar between both technologies. 

Original Title: Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome. The HOST-Reduce-Polytech-ACS trial.

Reference: presentado por Kim HS en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....